7-117611622-G-C
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM1PM2PP3_ModeratePP5_Very_Strong
The NM_000492.4(CFTR):c.3181G>C(p.Gly1061Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000186 in 1,613,334 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 13/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★).
Frequency
Consequence
NM_000492.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CFTR | NM_000492.4 | c.3181G>C | p.Gly1061Arg | missense_variant | 20/27 | ENST00000003084.11 | NP_000483.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CFTR | ENST00000003084.11 | c.3181G>C | p.Gly1061Arg | missense_variant | 20/27 | 1 | NM_000492.4 | ENSP00000003084.6 |
Frequencies
GnomAD3 genomes AF: 0.00000658 AC: 1AN: 152058Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.00000399 AC: 1AN: 250828Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135556
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1461158Hom.: 0 Cov.: 30 AF XY: 0.00000138 AC XY: 1AN XY: 726878
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152176Hom.: 0 Cov.: 31 AF XY: 0.0000134 AC XY: 1AN XY: 74398
ClinVar
Submissions by phenotype
Cystic fibrosis Pathogenic:6
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 27, 2023 | The p.G1061R pathogenic mutation (also known as c.3181G>C and c.3313G>C), located in coding exon 20 of the CFTR gene, results from a G to C substitution at nucleotide position 3181. The glycine at codon 1061 is replaced by arginine, an amino acid with dissimilar properties. This variant has been confirmed in trans and identified likely in trans with a CFTR pathogenic variant in multiple individuals with clinical features of cystic fibrosis and CFTR-related disorders including, but not limited to: elevated sweat chloride levels, pulmonary disease, and pancreatic insufficiency (Bienvenu T et al. Hum Mutat, 1996;7:376-7; Mercier B et al. Genomics, 1993 Apr;16:296-7; Ravnik-Glavac M et al. Hum Mutat, 2002 Apr;19:374-83; Sala MA et al. J Cyst Fibros, 2021 Mar;20:356-363; Ambry internal data). In one functional study, this mutation was observed to result in protein misprocessing and failure of protein maturation (Seibert FS et al. J Biol Chem. 1996;271(25):15139-45). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Nov 22, 2019 | Variant summary: CFTR c.3181G>C (p.Gly1061Arg) results in a non-conservative amino acid change located in the ABC transporter type 1, transmembrane domain (IPR011527) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 250828 control chromosomes (gnomAD). c.3181G>C has been reported in the literature in individuals affected with Cystic Fibrosis (e.g. Alper_2004, Bienvenu_1995, Chertkoff_1997, Mercier_1993). These data indicate that the variant is likely to be associated with disease. Experimental evidence evaluating an impact on protein function demonstrated the variant to cause misprocessing and failure of maturation of CFTR resulting in its retention in the endoplasmic reticulum (Seibert_1996). Three ClinVar submitters including an expert panel (CFTR2) (evaluation after 2014) cite the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | May 13, 2022 | This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 1061 of the CFTR protein (p.Gly1061Arg). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with cystic fibrosis (PMID: 7683628, 8723695, 9084934; The Clinical and Functional TRanslation of CFTR (CFTR2) at http://cftr2.org). ClinVar contains an entry for this variant (Variation ID: 53672). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects CFTR function (PMID: 8662892). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Johns Hopkins Genomics, Johns Hopkins University | Feb 15, 2021 | - - |
Pathogenic, reviewed by expert panel | research | CFTR2 | Mar 17, 2017 | - - |
Pathogenic, criteria provided, single submitter | curation | CFTR-France | Jan 29, 2018 | - - |
not specified Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Feb 02, 2019 | The CFTR c.3181G>C, p.Gly1061Arg variant has been reported in cystic fibrosis patients (Alper 2004, Mercier 1993, Visich 2002, SickKids CFTR database, CFTR2 database), with variable presentation of pancreatic insufficiency (CFTR2 database). Functional characterization of the variant protein indicates that chloride conductance is severely impaired (CFTR2 database). The variant is listed in the ClinVar database (Variation ID: 53672), in the dbSNP variant database (rs142394380), and observed in the general population databases at a frequency of 0.02 percent in the 1000 Genomes Project, and 0.0077 percent in the Exome Variant Server. The glycine at residue 1061 is highly conserved, and computational algorithms (Align GV/GD, Mutation Taster, PolyPhen-2, SIFT) predict that the variant has an impact on the protein. Based on the above information, the variant is classified as moderately pathogenic. References: CFTR2 database: https://cftr2.org/ Link to p.Gly1061Arg in SickKids database: http://www.genet.sickkids.on.ca/cftr/MutationDetailPage.external?sp=443 Alper OM et al. Identification of novel and rare mutations in California Hispanic and African American cystic fibrosis patients. Hum Mutat. 2004 Oct;24(4):353. Mercier B et al. Identification of eight novel mutations in a collaborative analysis of a part of the second transmembrane domain of the CFTR gene. Genomics. 1993 16(1):296-7. Visich A et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. Clin Genet. 2002 Mar;61(3):207-13. - |
CFTR-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Aug 28, 2017 | - - |
Cystic fibrosis;C0403814:Congenital bilateral aplasia of vas deferens from CFTR mutation Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | - | - - |
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Mar 02, 2018 | - - |
Bronchiectasis with or without elevated sweat chloride 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Jan 30, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at